Search Results

• Craniopharyngioma - Identifying Bio Targets for Medical Therapy

  Advancing Treatment for Pediatric Craniopharyngioma: Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy

• Tipifarnib and Naxitamab for Relapsed/​Refractory Neuroblastoma

  Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

• RESTORE: Re-do TAVR for TAVR Failure

  RESTORE Study (REdo tranScatheter aortic valve replacement for Transcatheter aOrtic valve failuRE)

• Vivistim Registry for Paired VNS Therapy (GRASP)

  Vivistim Registry for Paired VNS Therapy (GRASP)/(Bayfront)

• A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions

  A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions

• A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

  A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

• PRONE SPINE

  Prone position versus lateral or mixed positioning for lateral approach to spine

• A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old With First Relapse

• Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

• Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  A Phase II study of Naxitamab added to induction Therapy for Subjects with Newly Diagnosed High Risk Neuroblastoma